Outcomes Insights Team
Dr. Danese’s expertise is in the design and analysis of studies using observational data, creation of budget impact and cost-effectiveness models, and the design of population-based simulation models. He has over 50 peer-reviewed manuscripts published in journals including JAMA, Blood, Journal of Bone and Mineral Research, Cancer, American Journal of Kidney Diseases, Value in Health, and the Journal of Clinical Endocrinology and Metabolism.
Dr. Danese is a collaborator with the Observational Health Data Science and Informatics (OHDSI) collaborative, helping to develop open-source tools to improve the conduct of observational studies. He is also a member of the following organizations: the American Statistical Association, Academy Health, the Society for Medical Decision Making, the International Society for Pharmacoepidemiology, the American Medical Informatics Association, and the International Society for Pharmacoeconomics and Outcomes Research.
direct line: +1.805.498.0034
Prior to joining Outcomes Insights, Inc., Dr. Doan worked for 5 years at Cerner LifeSciences (formerly Zynx Health). In this capacity, he worked on a wide variety of projects supporting product development for clients in major pharmaceutical and biotech companies including evidence synthesis (e.g., literature review, meta-analysis), economic evaluation (e.g., cost-effectiveness analysis, cost-utility analysis, cost-of-illness and budget impact estimation), value assessment (e.g., global value dossier, AMCP dossier) and secondary database research. Prior to this, Dr. Doan spent 2 years at Health Process Management conducting cost-effectiveness evaluation alongside clinical trials.
direct line: +1.805.367.7485
Dr. Lubeck also has been involved in research studies examining the efficacy and cost-utility of therapies for rheumatoid arthritis, osteoarthritis, HIV-infection, gastrointestinal conditions, cardiovascular disease, chronic kidney disease, multiple solid tumors, and hematologic malignancies. In addition, Deborah has been involved in the design and validation of several patient-reported quality of life instruments, including instruments for rheumatoid arthritis, osteoarthritis, HIV-infection, prostate cancer, and patient satisfaction with care.
Dr. Lubeck worked in Health Economics and Outcomes Research Departments at Amgen, Inc. and Genentech, Inc. and was Vice President, Health Economics and Outcomes Research at ICON and PAREXEL. Prior to her work in industry she was on the faculty of the Department of Urology at the University of California, San Francisco and the Department of Immunology, Division of Rheumatology, Stanford University. She has a BA from Northwestern University and a Ph.D. in Economics from the University of California, Berkeley. She currently serves on the Editorial Board of Drugs in Context and is a peer-reviewer for multiple clinical and health services research journals.
direct line: +1.805.367.7484
For the past 14 years, Dr. Gleeson has worked in health services research. As a consultant, she focuses on preparing, managing and analyzing data using a number of software packages (R, SAS, Stata). Areas of analysis she publishes in are utilization and cost, prevalence of disease, course and extent of disease and methodology. Therapeutic areas that she has concentrated on include: oncology (lymphoma, breast, ovarian, prostate, lung), diabetes, rheumatoid arthritis, immune thrombocytopenic purpura, chronic kidney disease and end stage kidney disease.
Dr. Gleeson specializes in conducting multivariate quantitative analysis and secondary analysis on longitudinal and cross sectional data and has extensive experience with a wide assortment of data sources such as Medicare, SEER, USRDS, CPRD, NHANES, NIS, Marketscan, Humedica, MedAssets, and Health Facts.
direct line: +1.805.367.7491
direct line: +1.805.367.7483
Ms. Duryea’s current projects at Outcomes Insights include building economic models, data analysis, and medical data research, including medical coding and analyzing payer policies. Ms. Duryea is also a frequent contributor to the OHDSI community, where she has helped develop ETL documents for various datasets and provided expertise on OHDSI’s vocabulary development.
direct line: +1.805.367.7481
In recent years, he created an open-source language (ConceptQL) that unambiguously defines and structures a set of criteria in a flexible, easily parse-able, and human readable, format to serve as a foundation for the Jigsaw suite of tools. He is also a regular contributor to several projects in the OHDSI community
direct line: +1.805.367.7486
Previously, Sherry was a Director of Marketing at Amgen, with responsibility for a U.S. and global nephrology product launch, a Vice President at Migliara/Kaplan Associates (now Kantar Health), and a Regulatory Review Officer at the FDA with responsibility for drug labeling and other branding materials for neuropharmacology, oncology, respiratory, and anti-infectives drug products. She began her career as a sales & marketing representative for Eli Lilly and Company. Over this time, she has cultivated experience in a broad array of therapeutic areas including neurology, psychiatry gastroenterology, oncology, anti-infectives, respiratory, women’s health, and nephrology. Sherry earned a M.B.A. from the University of Virginia’s Darden School of Business and a B.S. in Chemistry from the University of Virginia.
Previously, Daryl was a Senior Vice President at Lehman Brothers responsible for strategic investments, a Director and Global Head of Marketing at Citigroup where he managed product development, marketing and sales force activities, and a Director of Strategic Planning and Business Development at American Express, responsible for the development of new businesses and strategic investments. He began his career as a management consultant with Corporate Decisions, Inc. (now Oliver Wyman), focused on customer-driven growth strategies. Daryl has a B.A. from Brown University (Phi Beta Kappa, Magna Cum Laude) and an M.B.A. from Yale University.